CCRM Australia
CCRM Australia is a Melbourne-based not-for-profit that accelerates commercialisation of regenerative medicine discoveries for Australian researchers and biotech companies through partnerships, programs, and its Global CCRM network affiliation.
- Company typePrivate
- Founded2018
- HeadquartersClayton, Australia
- Headcount1–10
- GTM typeB2B
- OfferingServices
What CCRM Australia does
CCRM Australia (Centre for Commercialisation of Regenerative Medicine Australia) is an Australian not-for-profit organization that accelerates the translation and commercialisation of regenerative medicine discoveries for Australian researchers and emerging biotechnology companies. Originally established as a non-incorporated joint venture in 2018 and incorporated as a not-for-profit in March 2022, the organization operates from the Australian Regenerative Medicine Institute (ARMI) at Monash University Clayton Campus and serves as the Australian hub within the Global CCRM network, alongside centres in Canada, the Nordics, Israel, Japan, Europe, and Singapore.
Its offering is structured as a suite of programs rather than discrete products: Technology Evaluations assesses commercial viability of novel regenerative medicine technologies; the Attract Unit engages talent, companies, and investment; the Clarity Unit publishes market insights; FundingIP supports funding and intellectual property strategy; the T1D Program targets Type 1 Diabetes translation; and Workshop, Roundtable, and Scientific Symposium programs convene industry, academia, and government stakeholders. Underlying its approach is a commercialization methodology transferred from CCRM Canada — in-licensing, value-adding development, out-licensing, and bundling technologies into spin-outs — adapted for the Australian context.
CCRM Australia's business model is partnership- and grant-driven rather than transactional. The organization engages in direct enterprise partnerships (e.g., strategic advisory for SMSbiotech Australia's Phase 1 trial, co-organized European market entry workshops with INITS, SMART CRC co-development with the University of Queensland) and earns no disclosed revenue from product sales. Specific pricing, headcount, and funding sources are not publicly disclosed, consistent with its not-for-profit structure focused on ecosystem impact rather than commercial monetization.
CCRM Australia firmographics
Firmographics- Name
- CCRM Australia
- Legal name
- Centre for Commercialisation of Regenerative Medicine Australia
- Website
- https://ccrmaustralia.com.au
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- CCRM Australia is a Melbourne-based not-for-profit that accelerates commercialisation of regenerative medicine discoveries for Australian researchers and biotech companies through partnerships, programs, and its Global CCRM network affiliation.
- Ownership category
- akta.pro rank
Where CCRM Australia is headquartered
LocationHeadquarters
- HQ city
- Clayton
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
CCRM Australia business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
CCRM Australia product offering
Product offeringCore offering
CCRM Australia is a not-for-profit organization that accelerates the commercialization of regenerative medicine discoveries in Australia. It delivers strategic partnerships, funding and IP support, advanced manufacturing capabilities for cell and gene therapies, and a coordinated suite of programs (Technology Evaluations, Attract Unit, Clarity Unit, Workshop, Roundtable, Scientific Symposium, FundingIP, and T1D) to move regenerative medicine from bench to bedside. The organization applies a commercialization model adapted from CCRM Canada and operates as part of the Global CCRM network.
Product overview
CCRM Australia operates as a not-for-profit organization that accelerates regenerative medicine commercialization through strategic programs and services. The offering consists of a coordinated suite of programs including Technology Evaluations (for assessing novel technologies), the Attract Unit (for talent and investment engagement), the Clarity Unit (for market insights including AI applications), the Workshop Program (for education on research translation), the Roundtable Program (for stakeholder engagement), the Scientific Symposium Program (for knowledge sharing), FundingIP (for IP and funding support), and the T1D Program (for diabetes-focused research). The organization is modeled on CCRM Canada and is part of the Global CCRM network, leveraging international expertise to support Australian regenerative medicine discoveries from bench to bedside.
Differentiator
Problem solved
Functional benefit
Products and services
- Technology Evaluations
Quantifiable outcome
- Process optimisation on a cell therapy resulting in a 60% reduction in cost of goods (from CCRM Canada)
Companies that use CCRM Australia
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles2 records
CCRM Australia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature1 record
CCRM Australia partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and flagship.
- SMSbiotechcoreStrategic collaboration with SMSbiotech Inc., headquartered in San Diego, to provide strategic and commercial advisory services to its Australian subsidiary SMSbiotech Australia Pty Ltd. SMSbiotech is pioneering advanced therapies through proprietary platform technology spanning multiple therapeutic areas including respiratory disease. The company has a candidate in Phase 1 Clinical Trial in Australia.
- INITScorePartnership with INITS, a dynamic consulting firm supporting biotech companies throughout pharmaceutical development journey. INITS has over 12 years of experience and has supported more than 250 clients in France and internationally. With expertise in biologics (C>, EVs, mAbs, proteins), INITS covers CMC, Regulatory, Clinical Supply, Quality Assurance, and Audits. Partnership includes co-organising workshops about internationalising into Europe for clinical trials and commercialisation.
- CCRM NordiccoreCCRM Australia maintains continued international collaboration with CCRM Nordic as part of the Global CCRM network.
- University of QueenslandcoreCo-development of the SMART CRC (Strategic Research Centres) application with the University of Queensland as part of strategic contributions to major initiatives.
- CCRM (Canada)flagshipCCRM Australia was modelled on the highly successful CCRM in Canada and maintains ongoing international collaboration. CCRM has become globally recognised as a translation centre and leading global commercial hub for regenerative medicine and cell therapy since its inception in 2011. The partnership provides access to a demonstrated commercialization model and sector-specific expertise.
- Monash University (ARMI)flagshipCCRM Australia is located at the Australian Regenerative Medicine Institute (ARMI) at Monash University Clayton Campus. CCRM approached ARMI to establish an Australian 'hub' modelled along the CCRM operational model. This hub is being developed in parallel with other emerging hubs in Israel, Japan, Europe and Singapore.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
CCRM Australia competitors and assessment
Company assessmentDirect peers
- BioCurate: BioCurate is an Australian not-for-profit joint venture between Monash and Melbourne universities that commercializes early-stage therapeutic discoveries, directly overlapping CCRM Australia's mandate of moving academic biomedical research toward commercialization in Australia.
- CCRM Nordic: CCRM Nordic is a sister hub within the Global CCRM network offering the same regenerative medicine commercialization and advanced manufacturing model in the Nordics, making it a structurally identical peer.
- Cell and Gene Therapy Catapult: Cell and Gene Therapy Catapult is a UK-based innovation and technology catapult focused on advancing cell and gene therapy commercialization, development, and manufacturing capabilities — a close structural analogue to CCRM Australia's offerings.
- Therapeutic Innovation Australia: Therapeutic Innovation Australia is an Australian NCRIS-enabled infrastructure network providing translational research capabilities to accelerate therapeutic development, operating as a complementary Australian commercialization platform.
- MaRS Discovery District: MaRS is a large Canadian innovation hub supporting commercialization of health and life science ventures; its model of integrating researchers, industry partners, and capital mirrors CCRM Australia's commercialization approach.
- CCRM (Canada): CCRM Canada's Centre for Commercialisation of Regenerative Medicine is the parent model and direct peer; CCRM Australia explicitly applies CCRM Canada's commercialization playbook and benefits from shared global consortium membership.
Broad incumbents
- JLABS (Johnson & Johnson Innovation): JLABS is a global network of biotech incubators operated by Johnson & Johnson Innovation providing lab space, mentorship, and commercialization support to early-stage biotechs — overlapping with CCRM Australia's incubation and acceleration role.
- Innovate UK Catapult Network: The Catapult Network is a UK network of technology and innovation centres supporting commercialization across sectors including cell and gene therapy; its structure mirrors the consortium-style support model CCRM Australia delivers.
Regional players
- MTPConnect: MTPConnect is an Australian Industry Growth Centre for the medical technology, biotechnology, and pharmaceuticals sector, providing similar sector-level commercialization, workforce, and funding support to Australian regenerative medicine initiatives.
Others
- Centre for Drug Candidate Optimisation (Monash): Adjacent Monash-based translational drug development capability; shares the same Monash University ecosystem that hosts CCRM Australia and provides overlapping translational support to Australian biotech discoveries.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
CCRM Australia social profiles
Digital presenceCCRM Australia financial estimates
Financial estimateRevenue estimate
Valuation estimate
CCRM Australia leadership team
Management profileNumber of profiles
CCRM Australia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CCRM Australia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CCRM Australia
What does CCRM Australia do?
CCRM Australia is a not-for-profit organization that accelerates the commercialization of regenerative medicine discoveries in Australia. It delivers strategic partnerships, funding and IP support, advanced manufacturing capabilities for cell and gene therapies, and a coordinated suite of programs (Technology Evaluations, Attract Unit, Clarity Unit, Workshop, Roundtable, Scientific Symposium, FundingIP, and T1D) to move regenerative medicine from bench to bedside. The organization applies a commercialization model adapted from CCRM Canada and operates as part of the Global CCRM network.
Is CCRM Australia a public or private company?
CCRM Australia is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was CCRM Australia founded?
CCRM Australia was founded in 2018. It employs 1 to 10 people.
Where is CCRM Australia based?
CCRM Australia is headquartered in Clayton, Australia, in the Oceania region.
Who are CCRM Australia's main competitors?
Direct peers on record are BioCurate, CCRM Nordic, Cell and Gene Therapy Catapult, Therapeutic Innovation Australia, MaRS Discovery District and CCRM (Canada). Broad incumbents are JLABS (Johnson & Johnson Innovation) and Innovate UK Catapult Network. MTPConnect is listed as a regional player. Centre for Drug Candidate Optimisation (Monash) is listed as an others.
Does CCRM Australia have an API?
No public API is recorded for CCRM Australia.